Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
EAST RUTHERFORD, N.J., Feb. 15, 2018 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will participate in a fireside chat at the 2018 RBC Capital Markets Global Healthcare Conference on February 22, 2018 at 3:05 p.m. EST in New York City.
The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and a replay will be available for 90 days after the live event concludes.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact:
Stephanie LaFiura
IR Associate
Tel: +201 804 3037
Email: [email protected]
